Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants
- PMID: 12455049
- DOI: 10.1002/ijc.10743
Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants
Abstract
Mirk/dyrk1B is an arginine-directed protein kinase, which functions as a transcriptional activator and mediates serum-free growth of colon carcinoma cells by an unknown mechanism. We now report that turnover of the cdk inhibitor p27(kip1) and the G(1)-phase cyclin cyclin D1 is enhanced in each of 4 Mirk stable transfectants compared to vector control transfectants and Mirk kinase-inactive mutant transfectants. This enhanced turnover is proteasome-dependent and leads to lower protein levels of both p27(kip1) and cyclin D1. Lower protein levels of the cdk inhibitor p21(cip1) were also observed in the 4 Mirk stable transfectants. Mirk did not alter the activity of a p27(kip1) promoter construct or p27(kip1) mRNA levels by stable expression, indicating that the decrease in p27(kip1) protein levels was due to a posttranscriptional mechanism. These data are consistent with mirk enhancing the expression of some component common to the proteolysis of both p27(kip1) and cyclin D1.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.J Biol Chem. 2004 May 21;279(21):22498-504. doi: 10.1074/jbc.M400479200. Epub 2004 Mar 9. J Biol Chem. 2004. PMID: 15010468
-
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658
-
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.J Cell Physiol. 2003 Apr;195(1):139-50. doi: 10.1002/jcp.10239. J Cell Physiol. 2003. PMID: 12599217
-
Negative regulators of cyclin-dependent kinases and their roles in cancers.Cell Mol Life Sci. 2001 Nov;58(12-13):1907-22. doi: 10.1007/pl00000826. Cell Mol Life Sci. 2001. PMID: 11766887 Free PMC article. Review.
-
p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs.Curr Med Chem. 2005;12(14):1589-605. doi: 10.2174/0929867054367149. Curr Med Chem. 2005. PMID: 16022660 Review.
Cited by
-
N-Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents.Cancers (Basel). 2024 May 27;16(11):2033. doi: 10.3390/cancers16112033. Cancers (Basel). 2024. PMID: 38893153 Free PMC article.
-
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.Cell Mol Life Sci. 2016 Feb;73(4):883-900. doi: 10.1007/s00018-015-2032-x. Epub 2015 Sep 7. Cell Mol Life Sci. 2016. PMID: 26346493 Free PMC article.
-
Mirk regulates the exit of colon cancer cells from quiescence.J Biol Chem. 2009 Aug 21;284(34):22916-25. doi: 10.1074/jbc.M109.035519. Epub 2009 Jun 19. J Biol Chem. 2009. PMID: 19542220 Free PMC article.
-
Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.Cancer Res. 2009 Apr 15;69(8):3317-24. doi: 10.1158/0008-5472.CAN-08-2903. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351855 Free PMC article.
-
A form of the metabolic syndrome associated with mutations in DYRK1B.N Engl J Med. 2014 May 15;370(20):1909-1919. doi: 10.1056/NEJMoa1301824. N Engl J Med. 2014. PMID: 24827035 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous